Stem Cell-Derived Human Microglia With Reproducible Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating human microglial cells from pluripotent stem cells are inefficient and not reproducible, and there is a lack of effective protocols due to differences between rodent and human microglial cells.
Innovation Solution
A chemically defined medium-based method to differentiate pluripotent stem cells into CD14+ and/or CX3CR1+ microglial progenitor cells, followed by differentiation into ramified microglia using cytokines like IL-34, M-CSF, GM-CSF, and other factors, with a multi-step process involving specific cytokine combinations and timings.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rodent pluripotent stem cell differentiation protocols are used on human pluripotent stem cells, then the process can be initiated, but the differentiation is ineffective and not reproducible
Solution Approach 1:
The patent modifies the differentiation protocol by changing key parameters including the use of specific growth factors (IL-34, M-CSF, GM-CSF), cytokine combinations, and culture conditions that are optimized for human pluripotent stem cells rather than rodent cells. This parameter adjustment enables effective and reproducible differentiation of human PSCs into microglial cells.
Solution Approach 2:
The differentiation process is divided into distinct sequential stages: initial differentiation into myeloid progenitors, followed by specific differentiation into microglial progenitors expressing CD14 and/or CX3CR1, and final maturation into ramified microglia. This segmented approach allows optimization of each stage with appropriate cytokines and conditions.
2Reliability
If primary human microglial cells are obtained from human brain specimens, then authentic human microglia are obtained, but the availability is severely limited
Solution Approach 1:
The patent uses pluripotent stem cells as a preliminary source that can be expanded and differentiated in advance to generate large numbers of authentic human microglial cells. This eliminates the need to obtain cells from limited human brain specimens at the time of study, as cells can be generated on demand from PSC lines.
Solution Approach 2:
The patent creates in vitro copies of primary human microglial cells through differentiation of pluripotent stem cells. These cultured microglial cells replicate the functional and phenotypic characteristics of primary microglia, providing an unlimited supply for research without requiring additional human brain specimens.
3Ease of operation
If a simple differentiation protocol is used, then the process is easy to perform, but the differentiation efficiency and cell quality are insufficient
Solution Approach 1:
The protocol is segmented into distinct stages with specific cytokine treatments for each phase: myeloid progenitor generation, microglial progenitor differentiation, and microglial maturation. This structured segmentation maintains ease of performance while achieving high differentiation efficiency and cell quality through optimized conditions at each stage.
Solution Approach 2:
Specific parameters such as cytokine concentrations (IL-34, M-CSF, GM-CSF), treatment durations, and culture conditions are optimized to balance protocol simplicity with high differentiation efficiency. The standardized parameter settings make the protocol easy to follow while ensuring reproducible generation of high-quality microglial cells.
Data Source
AI summary
The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells. The present invention also provides cells produced using such methods, and both methods of treatment and methods of drug screening that use such cells. Also provided are various tissue culture media, tissue culture media supplements, and kits useful for the generation of human microglial progenitor cells and human microglial cells.